Document Detail


Synergistic cytotoxicity between dimethyl sulfoxide and antineoplastic agents against ovarian cancer in vitro.
MedLine Citation:
PMID:  3177534     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Dimethyl sulfoxide is a well-known differentiating agent that has been shown to inhibit tumor growth in vitro. We hypothesized that antineoplastic agents might show synergistic cytotoxicity when combined with 10% dimethyl sulfoxide. Twenty-four malignant ovarian tumors were removed and used in tests to determine the cytotoxicities of 10% dimethyl sulfoxide alone, each of six antineoplastic agents alone, and 10% dimethyl sulfoxide plus each antineoplastic agent. Cytotoxicity results for 10% dimethyl sulfoxide alone and each antineoplastic agent alone were used to evaluate each combination of dimethyl sulfoxide and an antineoplastic agent for synergy. There were 14 synergistic responses that were statistically significant at the p less than 0.01 confidence level between 10% dimethyl sulfoxide and an antineoplastic agent against the ovarian tumors. Seven of these responses were significant at the p less than 0.0003 level. This is strong evidence that true synergistic cytotoxicity occurs when an antineoplastic agent is combined with 10% dimethyl sulfoxide. We conclude that intraperitoneal delivery of antineoplastic agents in 10% dimethyl sulfoxide may be useful in the treatment of certain ovarian cancers.
Authors:
R F Pommier; E A Woltering; G Milo; W S Fletcher
Related Documents :
22781694 - Modeling and predicting clinical efficacy for drugs targeting the tumor milieu.
22351674 - Induction of non-apoptotic cell death in human oral squamous cell carcinoma cell lines ...
22360764 - Canine eyelid granular cell tumor: a report of eight cases.
22761304 - Cell-cycle control in urothelial carcinoma: large-scale tissue array analysis of tumor ...
6446524 - Evaluation of the immunocompetence of macrophages and the generation of t-cell-mediated...
11801554 - P73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  159     ISSN:  0002-9378     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  1988 Oct 
Date Detail:
Created Date:  1988-11-23     Completed Date:  1988-11-23     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  848-52     Citation Subset:  AIM; IM    
Affiliation:
Department of Surgery, Oregon Health Sciences University, Portland 97201.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anthraquinones / administration & dosage,  pharmacology
Antineoplastic Agents / administration & dosage*,  pharmacology
Cisplatin / administration & dosage,  pharmacology
Dimethyl Sulfoxide / administration & dosage*,  pharmacology
Doxorubicin / administration & dosage,  pharmacology
Drug Synergism
Female
Fluorouracil / administration & dosage,  pharmacology
Humans
Methotrexate / administration & dosage,  pharmacology
Ovarian Neoplasms / drug therapy,  pathology*
Tumor Cells, Cultured / drug effects
Vinblastine / administration & dosage,  pharmacology
Chemical
Reg. No./Substance:
0/Anthraquinones; 0/Antineoplastic Agents; 15663-27-1/Cisplatin; 23214-92-8/Doxorubicin; 51-21-8/Fluorouracil; 59-05-2/Methotrexate; 67-68-5/Dimethyl Sulfoxide; 84-65-1/9,10-anthraquinone; 865-21-4/Vinblastine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC 125 after intravenous and i...
Next Document:  Fetal heart rate patterns during labor: neurologic and cognitive development at six to nine years of...